Clinical trials: Lung Tumors
Non-Small Cell Lung Cancer, Pancreatic Cancer
A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT03819387
- Testing
- NBF-006
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Nitto BioPharma, Inc.
Non-small Cell Lung Cancer With EGFR-Activating Mutations
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib in patients with locally advanced or metastatic…
- Trial name
- NCT01774721
- Testing
- Dacomitinib (PF-00299804), Gefitinib
- Where
- 52 sites in China, Hong Kong and 5 more
- Volunteers
- 452 people
- Sponsor
- Pfizer
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NSCLC
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer
Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice.
- Trial name
- IMMUNOBZH (NCT04858204)
- Where
- 7 sites in France
- Volunteers
- 259 people
- Sponsor
- University Hospital, Brest
Lung Cancer
Computed Tomography (CT) Guided Lung Biopsy: Core or Fine Needle Aspiration
This study is a comparison of core needle biopsy with fine needle aspiration biopsy in the evaluation of lung nodules.
- Trial name
- NCT00188526
- Testing
- lung biopsy
- Where
- Canada
- Sponsor
- University Health Network, Toronto
FGFR1 Gene Amplification, FGFR1 Gene Mutation
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02965378
- Testing
- Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
- Where
- 1,084 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Neoplasms, Neoplasms, Glandular and Epithelial
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02897778
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
NSCLC
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
The Single-arm, multicenter study evaluate the safety and efficacy of Anlotinib Hydrochloride combined with EGFR TKIs in treating Advanced NSCLC With acquired Resistance to EGFR TKIs
- Trial name
- NCT04007835
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Association of Clinical Trials
Small Cell Lung Cancer
BMS-986012 in Relapsed/Refractory SCLC
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with…
- Trial name
- NCT02247349
- Testing
- BMS-986012 (anti-fucosyl-GM1), Nivolumab
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
NSCLC, Neoadjuvant Therapy
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
This is a randomized, open-label, multicenter phase II study. The trial plans to enroll 164 subjects with resectable stage IIA-IIIB (N2) NSCLC.
- Conditions
- NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
- Trial name
- NEOINSPIRE (NCT07086326)
- Testing
- Ivonescimab+Chemo, Penpulimab+Chemo
- Where
- 5 sites in China
- Volunteers
- 164 people
- Sponsor
- Yang Fan, MD
Stage IV Non-small Cell Lung Cancer
KN046 in Patients With Advanced Non-small Cell Lung Cancer
This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.
- Trial name
- NCT03838848
- Testing
- KN046, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Lung Cancer
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
In this single-arm, phase II study, we aimed to evaluate the efficacy and safety of sac-TMT plus bevacizumab in patients with advanced non-squamous NSCLC who showed disease progression on or after first-line ICI plus…
- Trial name
- NCT07244926
- Testing
- Sacituzumab tirumotecan plus bevacizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Soft Tissue Sarcoma, Pulmonary Metastasis
Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
This study is a multi-centre, open-label, single-arm, 3+3 Phase 1b/ and Phase II. Phase 1b is aimed to determine the maximum-tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) based on safety reporting.
- Trial name
- ANNA-SARC (NCT05518526)
- Testing
- Liposomal Annamycin (L-Annamycin)
- Where
- Poland
- Volunteers
- 64 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Breast Cancer, Lung Cancer
Implementation, Effectiveness and Impact of a Value Based Intervention for Patients with Breast or Lung Cancer
VOICE project aims to guide health services in their reorganization towards the provision of the highest value care for the patient at the best cost. VOICE is targeted to patients with breast and lung cancer.
- Trial name
- VOICE (NCT04960735)
- Testing
- VOICE intervention
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 1,007 people
- Sponsor
- Biosistemak Institute for Health Systems Research
Male Breast Cancer, Recurrent Breast Cancer
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in treating patients who have solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer
- Trial name
- NCT00028535
- Testing
- trastuzumab, paclitaxel, recombinant interleukin-12
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Nsclc
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
This is a Phase I study of repotrectinib in combination with osimertinib in patients with advanced or metastatic EGFR mutant non small cell lung cancer (NSCLC).
- Trial name
- TOTEM (NCT04772235)
- Testing
- Repotrectinib, Osimertinib
- Where
- 4 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Instituto Oncológico Dr Rosell
Non-Small Cell Lung Cancer, Stage IIIB or IV
Alimta and Gemcitabine in Non-Small Cell Lung Cancer
The aims of this study are: (1) to assess the safety and activity of gemcitabine plus Alimta (pemetrexed) regimen (GA regimen) in patients with advanced NSCLC patients in the context of a randomized trial, and (2) to compare the…
- Trial name
- ANGEL (NCT00434135)
- Testing
- gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Southern Italy Cooperative Oncology Group
Lung Cancer (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease)
Risk-Based Lung Cancer Detection in COPD Patients
The goal of the interventional study is to evaluate whether risk-based stratification using the PLCOm2012 model and a machine learning (ML) model can identify patients with chronic obstructive pulmonary disease (COPD) who are at…
- Trial name
- ELUCID (NCT07848815)
- Testing
- Risk-based prediction models
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Vejle Hospital
Colorectal Cancer
Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery
Surgery for colorectal cancer is a major surgery. People above the age of 60 tend to have a higher risk of complications. Some studies indicate that senior cancer patients might benefit from a home support after surgery by a…
- Trial name
- NCT01416168
- Testing
- McCorkle Model Intervention
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.